Meyahealth
HomeGeneticsConditionMultiple sulfatase deficiency
Back to Condition
Multiple sulfatase deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Multiple Sulfatase Deficiency

Multiple sulfatase deficiency is a rare genetic condition that primarily affects the brain, skin, and skeleton, with severity ranging from neonatal to juvenile onset.

Overview

Multiple sulfatase deficiency is a condition that mainly affects the brain, skin, and skeleton. Because the signs and symptoms vary widely, researchers have classified the condition into three distinct types: neonatal, late-infantile, and juvenile.

Neonatal Type

The neonatal type is the most severe form, with signs and symptoms appearing soon after birth. Affected individuals experience deterioration of tissue in the nervous system (leukodystrophy), which can contribute to movement problems, seizures, developmental delay, and slow growth. Other characteristic features include:

  • Dry, scaly skin (ichthyosis)
  • Excess hair growth (hypertrichosis)
  • Skeletal abnormalities, including abnormal side-to-side curvature of the spine, joint stiffness, and dysostosis multiplex (a specific pattern of skeletal abnormalities seen on x-ray)
  • Distinctive facial features
  • Hearing loss, heart malformations, and an enlarged liver and spleen (hepatosplenomegaly)

Many of the signs and symptoms of neonatal multiple sulfatase deficiency worsen over time.

Late-Infantile Type

The late-infantile type is the most common form of multiple sulfatase deficiency. It is characterized by normal cognitive development in early childhood followed by a progressive loss of mental abilities and movement (psychomotor regression) due to leukodystrophy or other brain abnormalities. Individuals with this form typically have fewer features than those with the neonatal type but often present with ichthyosis, skeletal abnormalities, and coarse facial features.

Juvenile Type

The juvenile type is the rarest form. Signs and symptoms appear in mid- to late childhood. Affected individuals have normal early cognitive development but subsequently experience psychomotor regression; however, this regression usually occurs at a slower rate than in the late-infantile type. Ichthyosis is also common in this form.

Prognosis

Life expectancy is shortened in individuals with all types of multiple sulfatase deficiency. Typically, affected individuals survive only a few years after the signs and symptoms of the condition appear, though life expectancy varies depending on the severity of the condition and how quickly the neurological problems worsen.

Frequency

Multiple sulfatase deficiency is estimated to occur in 1 per million individuals worldwide. More than 140 cases have been reported in the scientific literature.

Causes & Genetics

Multiple sulfatase deficiency is caused by mutations in the SUMF1 gene. This gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones.

Most SUMF1 gene mutations severely reduce the function of the FGE enzyme or lead to the production of an unstable enzyme that is quickly broken down. Because the FGE enzyme modifies all known sulfatase enzymes, the activity of multiple sulfatases is impaired. Sulfate-containing molecules that are not broken down build up in cells, often resulting in cell death. The death of cells in particular tissues, specifically the brain, skeleton, and skin, causes many of the signs and symptoms of multiple sulfatase deficiency.

Research indicates that mutations leading to reduced FGE enzyme function are associated with less severe cases, whereas mutations leading to the production of an unstable FGE enzyme tend to be associated with more severe cases.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Austin syndrome
  • Juvenile sulfatidosis, Austin type
  • MSD
  • Mucosulfatidosis

Frequently Asked Questions

Baseline echocardiography and liver ultrasound are done at diagnosis. After that, cardiac evaluation (echocardiogram and ECG) is recommended every 6–12 months, or sooner if symptoms like fatigue, edema, or arrhythmias appear. Liver enzymes and abdominal ultrasound should be checked at least annually, with more frequent testing if there are signs of hepatomegaly or abnormal labs.
Diagnosis relies on measuring the activity of several sulfatase enzymes in cultured fibroblasts, leukocytes, or dried blood spots. A markedly reduced activity of at least two different sulfatases confirms the biochemical defect. Genetic confirmation is then obtained by sequencing the SUMF1 gene from a blood sample, which identifies pathogenic mutations.
multidisciplinary approach works best: regular physiotherapy to maintain joint range of motion, occupational therapy for fine‑motor skills, and speech therapy if oral motor function declines. Skin care with emollients reduces ichthyosis cracking, and hearing aids address sensorineural loss. Nutritional support, including a high‑calorie diet and vitamin D supplementation, helps counter growth failure.
few early‑phase trials are investigating recombinant sulfatase enzymes delivered intravenously or via intrathecal routes, and gene‑editing approaches using AAV vectors to restore SUMF1 function. Eligibility typically requires a confirmed genetic diagnosis, stable organ function, and enrollment at a specialized center. Ask your metabolic specialist about current trial listings on clinicaltrials.gov.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ